Bleeding after total knee arthroplasty increases the risk of pain, delayed rehabilitation, blood transfusion, and transfusion-associated complications. The authors compared pre-and postoperative decreases in hemoglobin as a surrogate for blood loss in consecutive patients treated at a single institution by the same surgeon (J.L.C.) using conventional hemostatic methods (electrocautery, suturing, or manual compression) or a gelatin and thrombin-based hemostatic matrix during total knee arthroplasty. Data were collected retrospectively by chart review. The population comprised 165 controls and 184 patients treated with hemostatic matrix. Median age was 66 years (range, 28-89 years); 66% were women. The arithmetic mean6SD for the maximal postoperative decrease in hemoglobin was 3.1860.94 g/dL for controls and 2.1960.83 g/dL for the hemostatic matrix group. Least squares means estimates of the group difference (controls-hemostatic matrix) in the maximal decrease in hemoglobin was 0.96 g/dL (95% confidence interval, 0.77-1.14 mg/dL; P,.0001). Statistically significant covariate effects were observed for preoperative hemoglobin level (P,.0001) and body mass index (P=.0029). Transfusions were infrequent in both groups. The frequency of acceptable range of motion was high (control, 88%; hemostatic matrix, 84%). In both groups, overall mean tourniquet time was approximately 1 hour, and the most common length of stay was 3 to 5 days. No serious complications related to the hemostatic agent were observed. These data demonstrate that the use of a flowable hemostatic matrix results in less reduction in hemoglobin than the use of conventional hemostatic methods in patient undergoing total knee arthroplasty.
P ostoperative bleeding into joints is a major risk factor following arthroplasty, causing the formation of hematomas, increasing pain, and delaying recovery. Reported estimates of blood loss during total knee arthroplasty (TKA) in which electrocautery and other conventional methods are used vary from approximately 450 to .1000 mL. [1] [2] [3] [4] Higher estimates of >1900 mL were reported when blood loss was calculated based on pre-and postoperative hemoglobin levels.
1,2 High-volume blood loss increases the likelihood that a patient will require allogeneic blood transfusion, which introduces additional risks, such as the transmission of infectious agents, 5, 6 transfusion-associated lung injury, 7, 8 and transfusion reactions, 9 all of which may increase morbidity and mortality and lengthen the duration of hospitalization and rehabilitation. The control of hemostasis after TKA is further complicated by the concomitant use of anticoagulants to prevent the occurrence of deep venous thrombosis (DVT) and pulmonary emboli (PE).
Because conventional methods are not sufficient to control intra-and postoperative bleeding in many cases, various strategies, including the use of preoperative autologous blood donation and postoperative administration of epoetin alpha or antifibrinolytic agents have been implemented to reduce the effect of blood loss and prevent the need for allogeneic transfusions in patients undergoing orthopedic surgery. [10] [11] [12] Autologous platelet gels, prepared using platelet-rich plasma and containing multiple growth factors implicated in wound healing, initially showed promising results in a retrospective study of their use in TKA. 13 However, in subsequent small, prospective, randomized, controlled clinical studies, no statistically significant differences in objective outcomes of TKA were observed in patients treated with platelet gel vs those treated by conventional surgical hemostatic methods. 14, 15 Another approach involves the use of exogenous hemostatic agents that provide sealing, adhesive, or hemostatic functions, with hemostasis typically achieved by the inclusion of thrombin as a product component. For example, a gelatin-and human thrombin-based, flowable topical hemostatic matrix (FloSeal, Baxter Healthcare, Hayward, California) is approved for use in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical. 16 The efficacy and safety of this hemostatic matrix compared with an absorbable gelatin sponge plus thrombin (control) was shown in a large, randomized, multicenter trial of patients undergoing cardiac, vascular, or spinal surgery. Results from the overall study demonstrated that the proportion of patients who achieved hemostasis within 10 minutes was significantly higher for those in the hemostatic matrix group than in the control group (96% vs 77%, respectively; P,.001, Cochran-Mantel-Haenszel test). 16 In addition, median time to hemostasis was 3 times as fast in the hemostatic matrix group compared with the control group (2.0 vs 6.0 minutes, respectively). 16 These trial results led to the Food and Drug Administration approval in 1999. The effect of hemoglobin levels and transfusion requirements were not determined in these trials. The product also has been used in a variety of surgical specialties, including neurosurgery, 17, 18 gynecology, 19 urology, 20 and otolaryngology. 21, 22 Because these studies did not enroll patients undergoing orthopedic knee surgery, the product has not been examined for the control of bleeding following TKA. [16] [17] [18] [19] [20] [21] [22] Thus, this retrospective chart review study from a single institution was designed to assess outcome in terms of hemoglobin level, transfusion requirements, length of hospital stay, and range of motion (ROM) in patients undergoing TKA who received adjunctive treatment with the flowable gelatin-thrombin hemostatic matrix and in those treated with conventional surgical hemostatic methods.
Materials and Methods

Patients and Surgical Methods
All patients were treated at a single institution, by the same surgeon (J.L.C.), using similar surgical technique under the same protocol. Patients were treated consecutively in 2 groups. The historical control group comprised consecutive patients who underwent TKA using conventional techniques between January and October 2007. The hemostatic matrix group comprised consecutive patients who underwent TKA and were treated with adjunctive hemostatic matrix (FloSeal) between January and October 2008.
All patients had primary TKA. No revisions were included. Patients with previous knee surgeries, including arthroscopies, were included. All surgeries were performed by 1 surgeon (J.L.C.), who regularly performs TKA using similar surgical technique under the same protocol. The surgeon used similar surgical techniques for all patients, except for the addition of the hemostatic matrix to the second group. All patients received cemented cruciate-retaining or posterior cruciatesacrificing Genesis II implants (Smith & Nephew, Memphis, Tennessee). A tourniquet was used in all cases and inflated before incision. The mini quadriceps parapatellar approach was used. Electrocoagulation was used in both groups but was the primary source of hemostasis in the nonhemostatic matrix group. After the components were cemented in place in the hemostatic matrix group, 15 mL of the product was applied to all areas of exposed bleeding cancellous bone, posterior capsule, and medial and lateral release areas, and meniscal capsular areas. The hemostatic matrix was applied directly to the source/site of the bleeding and gently approximated with a damp sponge for 2 to 3 minutes. Excess product was irrigated away via bulb syringe, followed by deflat-ing the tourniquet. An additional 5 mL of hemostatic matrix was used to control remaining bleeding points. Both groups had standard 3-layer closure, cold units, and gentle compression applied. Continuous passive motion was not routinely used; early, full weight-bearing mobilization was encouraged.
All patients received 5 mg of warfarin (target international normalized ratio) of 1.8 to 2.8) beginning 1 night preoperatively as prophylaxis for the development of deep venous thrombosis (DVT) and pulmonary embolism (PE). Thereafter, the daily doses of warfarin were determined according to daily serum drug levels. Patients with a history of thromboembolisms also received 1 mg/kg of enoxaparin beginning on the night of surgery and then continuing twice daily thereafter until the warfarin reached a therapeutic effect. All patients received iron supplements for 30 days preoperatively. Patients received no epoetin alpha or autologous blood donations.
Study Design
The primary objective of this retrospective chart study was to compare outcomes related to blood loss among patients treated with conventional techniques and those treated with a hemostatic matrix after TKA. The endpoints examined were change in hemoglobin level, transfusion requirements, length of hospital stay, and range of motion (ROM). Change in hemoglobin level was used as a surrogate for estimated blood loss.
Data were collected retrospectively via a hospital chart review. Fields protected under HIPAA were not extracted from the chart. Because the study was conducted by retrospective chart review, the Institutional Review Board waived the requirement for informed consent. The following variables were recorded for patients in each group: sex, age, height, body mass index (BMI), procedure site, transfusion (y/n), number of units of packed red blood cells, preoperative hemoglobin level, postoperative hemoglobin level (days 1 and 2), length of stay, tourniquet time, type of anesthesia, use of anticoagulants, lower ROM, upper ROM, and acceptable ROM (y/n). Acceptable upper ROM was defined as at least 80º; acceptable lower ROM was defined as between -5 and 5º. American Society of Anesthesiology physical status score was collected for a subset of patients.
Statistical Analysis
Calculations were performed, and output was generated using SAS, SAS/ GRAPH, and SAS/STAT software, version 9.2 of SAS for Windows, 2002-2008 SAS Institute, Inc (Cary, North Carolina). The distribution of the response variable maximum decrease from hemoglobin was examined for deviations from assumptions necessary to perform the statistical analysis (eg, skewness, nonhomogeneity of variances, or the presence of extreme values).
The SAS procedure named MIXED was used to assess group differences with respect to maximum decrease in hemoglobin, with the model containing class variables group, sex and group by sex interaction and the covariates hemoglobin preoperatively, age, and body mass index (BMI). The MIXED procedure was also used to determine the least squares means estimates of the means, standard errors, and 95% confidence intervals (CIs) for the difference in mean change in hemoglobin between the historical control group and the hemostatic matrix group. An alpha level of .05 was used.
results
Patients
The historical control group comprised 165 patients, and the hemostatic matrix group comprised 184 patients. Demographic and surgical characteristics are shown in 
Change in Hemoglobin
The mean maximal decrease in hemoglobin postoperatively was 3.1860.94 g/dL for controls and 2.1960.83 g/dL for patients treated with the hemostatic matrix ( Figure  1) ; median decreases were similar in magnitude to mean decreases (Table 2) . Analysis using least squares means demonstrated a highly significant mean difference of 0.96 g/dL (95% CI, 0.77-1.14 g/dL; P,.0001) for the maximal decrease in hemoglobin between controls and patients treated with hemostatic matrix (Table 3) . The difference was significant for both men (mean, 1. Testing for group, covariate, and interaction effects showed significant effects of treatment group (P,.0001), preoperative hemoglobin level (P,.0001), and BMI (P5.0029), and nonsignificant effects for age, sex, and group by sex interactions (P5.5247, P5.4373, P5.1282, respectively). A higher preoperative hemoglobin level was associated with a greater postoperative decrease in hemoglobin ( Figure  2) , whereas a higher BMI was associated with a smaller postoperative decrease in hemoglobin (Figure 3 ).
Other Endpoints
The transfusion frequency was low in both treatment groups, with 6 of 165 (3.6%) controls and 17 (9.2%) of 184 patients in the hemostatic matrix group receiving >1 units of packed red blood cells. Lower and upper ROM results were acceptable for 145 of 164 (88%) controls and 155 (84%) of 183 patients treated 24 predicted that .3 million procedures will be performed annually by 2030. Although the attachment of prosthetic elements is now a relatively routine procedure, hemostatic management may continue to be challenging because of the concomitant need for low dose anticoagulation as a means for preventing DVT and PE, particularly in patients with comorbid conditions. Clinical evaluation of TKA methodology should include assessments of bleeding, but the accurate collection of total intraand postoperative blood loss is difficult and complicated by occult bleeding. For these reasons, blood loss is typically estimated based on body surface area and pre-and postoperative hemoglobin or hematocrit levels. 1, 2, 25 In the current retrospective chart review study, the authors used hemoglobin level as a surrogate for blood loss to evaluate the use of a hemostatic matrix compared with conventional hemostatic methods in patients undergoing TKA.
The hemostatic matrix used in the current study is a flowable agent comprising a bovine-derived gelatin matrix component that is mixed at the time of application with a human-derived thrombin component. Blood percolating through this matrix encounters a high concentration of human thrombin, which converts endogenous fibrinogen into fibrin, allowing a stable clot to form. 26 The gelatin granules conform and swell at the bleeding site, causing a local tamponade effect that restricts blood flow even further. This leads to high efficacy in a broad spectrum of bleeding scenarios, ranging from oozing to spurting. 27, 28 The matrix is resorbed by the body within 6 to 8 weeks, consistent with normal wound healing. The currently marketed product has been modified to include human, rather than bovine, throm- 
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Healio.com The new online home of ORTHOPEDICS | Healio.com/Orthopedics n Feature Article bin to minimize immunogenicity and potential coagulation disorders. 29 In the current study, the use of the hemostatic matrix significantly reduced postoperative decreases in hemoglobin compared with conventional hemostatic methods, with a mean difference of 0.96 g/dL (95% CI, 0.77-1.14 g/dL; P,.0001). This effect was observed in the overall population, as well as in men and women. Patient hemoglobin levels were not checked after postoperative day 2 unless justified by patient symptoms (standard practice in the authors' hospital), and therefore could not be analyzed. It is possible that hemoglobin level differences would be even greater at later time points. Because this was a retrospective study, patients were not treated in a concurrent, randomized manner; thus unknown factors could potentially confound the results. Analysis of covariates found no effect of age, sex, or group by sex interaction, and the likelihood of temporal confounding factors was decreased by the fact that all surgeries were consistently performed by the same surgeon, who has a high volume of patients undergoing TKA and uses similar surgical technique under the same protocol in all patients, regardless of the treat- 
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e790 ment assignment. The finding of similar tourniquet times in both cohorts indicates that unequal efforts to obtain hemostasis were unlikely to have occurred in either group. In addition, the preoperative protocol was identical for both groups, with all patients receiving iron supplementation for 30 days and none receiving erythropoietin or autologous blood donation. However, the preoperative hemoglobin level was positively correlated with the decrease in hemoglobin observed in this study (ie, higher preoperative hemoglobin was associated with a greater decrease in postoperative hemoglobin). This positive association likely reflects the higher dilution effect after blood loss in patients with a higher vs a lower baseline hemoglobin level, assuming similar blood volumes. The decrease in hemoglobin was negatively associated with BMI (ie, higher BMI was associated with smaller decrease in hemoglobin). This negative association likely reflects the higher blood volume and associated lower dilution effect after blood loss in patients with higher BMIs.
With 1 exception, all patients in the current study were started on warfarin prophylaxis for DVT and PE 1 night preoperatively, the effects of the drug would not have reached therapeutic levels by the time of surgery. Thus, efficacy in this study was demonstrated in the setting of partial, rather than therapeutic, anticoagulation. However, the same hemostatic matrix used herein was demonstrated to be effective even in heparinized patients undergoing cardiac surgery, with equally high success rates before (89% 17, 19 ) and after (96% 26, 27 ) protamine sulfate-induced reversal, whereas the control observed only efficacy in 36% 5, 14 and 75% 21, 28 respectively. 27, 28 The risk of transfusion is high in patients with preoperative hemoglobin levels ,10 g/dL (see review by Callaghan et al). 30 In the current study, few patients who received transfusions (,10% in both treatment groups) precluded analysis of transfusion risk with respect to demographic and treatment covariates. The decision to transfuse a patient is at the discretion of the attending anesthesiologist and is determined by hemoglobin levels and also by taking patient symptoms into consideration. Furthermore, comorbidity data were not available for examination of their contributions to the transfusion risk. Nevertheless, the data suggested that the overall transfusion rates, regardless of treatment group, were higher for patients who received enoxaparin in addition to warfarin as prophylaxis for DVT and PE. In a recently published prospective, randomized study of patients undergoing cardiac or thoracic aortic surgery, patients with intraoperative bleeding treated with the same hemostatic matrix used in the current study had a statistically significant decrease in frequency of transfusion compared with patients treated with other topical hemostatic products (28% vs 61%, P,.001), 31 suggesting that the use of this hemostatic matrix may decrease transfusions.
Other endpoints in the current study (length of stay and ROM) were similar for both treatment groups. Serious complications that could be related to the hemostatic matrix, such as infection, bleeding or acute reoperation, were not observed in this study. This finding is consistent with safety results from registration studies of the same hemostatic matrix in other surgical settings, where few mild adverse events were deemed related to the study agent and no serious complications were reported. The absence of infections and other serious complications is important because these types of adverse reactions have been previously associated with the use of gelatin-based hemostatic agents. 16 Although thrombin-based hemostatic agents have been widely used in European and other countries for several indications, including orthopedics, 3,32-36 they have not been widely applied to procedures such as TKA in the United States. Moreover, although randomized studies have been conducted with fibrin/thrombin-based hemostatic agents, 3, 32, 34 randomized studies of flowable gelatin/thrombin-based products for orthopedic surgery are lacking. To the authors' knowldge, the current study is the first report on the use of a thrombin-based hemostatic agent in patients undergoing TKA in the United States. The distinction between fibrin sealants and flowable thrombin-based products is important for orthopedic surgeons and patients because the 2 products differ in their mechanisms of action (tamponade effects and platelet activation by gelatin/collagen), their indications, and their safety considerations. FloSeal has a broader indication than fibrin sealants and can also be used for the treatment of more aggressive or brisk bleeding. 27 Results from the current study using a flowable thrombin-based hemostatic matrix are consistent with the results of small, randomized clinical trials on the use of fibrin/thrombin-based agents in TKA by Levy et al 34 in Israel, Molloy et al 37 in Ireland, and Wang et al 38 in the United States. All 3 studies reported significantly reduced postoperative blood loss for patients treated with fibrin sealant relative to standard surgical hemostasis. The Molloy study also found a similar result for tranexamic acid. The studies by Levy et al 34 and Wang et al 38 also found a benefit of fibrin sealant on hemoglobin levels. The mean decreases in hemoglobin in the fibrin sealant groups in the Wang et al 38 and Levy et al 34 studies were 2.060.21 g/dL and 2.561.0 g/dL, respectively, consistent with the observed mean decrease 2.1960.83 g/dL in the current study. The study by Levy et al 34 also reported a significantly lower frequency of transfusion among patients treated with the fibrin sealant.
Supporting the use of hemostasisinducing products in the surgical setting, a recent Cochrane meta-analysis examining the combined data from published studies of fibrin-containing hemostatic products in elective surgery showed trends for decreases in blood loss and the risk of transfusion for these agents rela-tive to conventional surgical hemostasis, particularly in the orthopedic setting. 39 As orthopedic surgeons gain familiarity and experience with thrombin-based hemostatic matrix products, their use will likely increase. The small number of trials and the relatively small sizes of the trials conducted indicate a need for larger, randomized trials of hemostatic matrix products in orthopedic surgery. The current retrospective chart review study provides the first report on use of a flowable gelatin/ thrombin-based hemostatic matrix for patients undergoing TKA in the United States. Results demonstrate that use of a gelatin/thrombin-based flowable hemostatic matrix results in less reduction in hemoglobin, a surrogate for blood loss, than the use of conventional hemostatic methods in patient undergoing TKA.
ConClusion
The current retrospective study extends the United States experience and demonstrates that the use of a flowable hemostatic matrix results in less reduction in hemoglobin, a surrogate for blood loss, than the use of conventional hemostatic methods in patients undergoing TKA.
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